Jungmann E, Malanyn M, Mortasawi N, Unterstöger E, Haak T, Palitzsch K D, Scherberich J, Schumm-Draeger P M, Usadel K H
Abteilung für Endokrinologie, Johann Wolfgang Goethe-Universität, Frankfurt/Main, Fed. Rep. of Germany.
Arzneimittelforschung. 1994 Mar;44(3):313-7.
In order to compare the long-term effects of nitrendipine (CAS 39562-70-4) and enalapril (CAS 75847-73-3) on variables of glomerular and tubular function in type 1 diabetes mellitus, a single-blind, randomised comparative 1-year study was carried out in microalbuminuric patients (6 women, 14 men, age, 30-58 years, duration of diabetes, 3-41 years, HbA1 sigma 5.5-10%). 10 patients were treated with 20 mg/d nitrendipine, 10 patients were treated with 10 mg/d enalapril. On the average, urinary albumin excretion was decreased by 38 +/- 4% by nitrendipine (p < 0.01 vs. before treatment) and by 21 +/- 8% by enalapril (p < 0.05 vs. before treatment). The excretion of alpha 1-microglobulin decreased by 35 +/- 10% and by 39 +/- 9%, respectively (p < 0.05 vs. before treatment). Creatine clearance rose by 20 +/- 30% during nitrendipine treatment (p < 0.05 vs. before treatment) but was unchanged during enalapril treatment. Total kidney volume decreased by 23 +/- 4% (p < 0.01) and by 14 +/- 6% (p < 0.05), respectively. Blood pressure fell by 8 +/- 1% systolic and by 13 +/- 1% (diastolic) in nitrendipine-treated patients (both p < 0.01) and by 10 +/- 1% and 13 +/- 1% in enalapril-treated patients (both p < 0.01). Thus, nitrendipine long-term treatment of microalbuminuric type 1 diabetic appeared to be as effective as the treatment with enalapril in preventing or postponing the progression of diabetic nephropathy.
为比较尼群地平(化学物质登记号39562 - 70 - 4)和依那普利(化学物质登记号75847 - 73 - 3)对1型糖尿病患者肾小球及肾小管功能变量的长期影响,对微量白蛋白尿患者(6名女性,14名男性,年龄30 - 58岁,糖尿病病程3 - 41年,糖化血红蛋白5.5 - 10%)进行了一项为期1年的单盲随机对照研究。10例患者接受20mg/d尼群地平治疗,10例患者接受10mg/d依那普利治疗。平均而言,尼群地平使尿白蛋白排泄量降低了38±4%(与治疗前相比,p<0.01),依那普利使其降低了21±8%(与治疗前相比,p<0.05)。α1 - 微球蛋白排泄量分别降低了35±10%和39±9%(与治疗前相比,p<0.05)。尼群地平治疗期间肌酐清除率升高了20±30%(与治疗前相比,p<0.05),而依那普利治疗期间肌酐清除率无变化。总肾体积分别降低了23±4%(p<0.01)和14±6%(p<0.05)。尼群地平治疗组患者收缩压下降了8±1%,舒张压下降了13±1%(均p<0.01),依那普利治疗组患者收缩压下降了10±1%,舒张压下降了13±1%(均p<0.01)。因此,尼群地平长期治疗微量白蛋白尿1型糖尿病患者在预防或延缓糖尿病肾病进展方面似乎与依那普利治疗同样有效。